You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華邦健康(002004.SZ):近日投資1億元成立華邦醫藥研究
格隆匯 03-09 16:19

格隆匯3月9日丨華邦健康(002004.SZ)公佈,公司為滿足公司醫藥戰略發展需要,持續提升藥物研發及技術創新體系建設,打造核心競爭力,培育新的利潤增長點,於近日投資1億元成立全資子公司華邦醫藥研究有限公司。

近日,公司已就此次投資成立全資子公司事宜完成工商登記手續,並取得了由重慶兩江新區市場監督管理局頒發的《營業執照》。

公司成立華邦醫藥研究有限公司旨在以公司現有的研發體系為基礎,通過強強整合,構建公司全新的藥物研發與信息共享中心,全面提高公司整體的研發實力,吸引高素質研發人才,構建全新的研發和技術轉化體系。有利於服務公司中長期大力發展新藥的戰略目標,是公司戰略落地的重要舉措,對公司未來發展具有積極意義。

根據目前公司的戰略目標,華邦醫藥研究有限公司實行全面佈局,分工協作,同步促進公司醫藥板塊各子公司的協同發展。華邦醫藥研究有限公司作為公司的新產品孵育中心,與各醫藥子公司在研發領域形成協作關係。

華邦醫藥研究有限公司以泛皮膚領域產品鏈、甾體激素產品鏈、抗感染類等領域藥物為主要研發方向,未來幾年將致力於改良型新藥、製藥新技術相關產品、首仿藥的研發,持續提升對創新藥的投入力度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account